PROCEPT BioRobotics Misses Revenue Targets Amid Strategic Realignment
Event summary
- PROCEPT BioRobotics reported $76.4M in Q4 2025 revenue, up 12% YoY but below expectations due to strategic realignment.
- The company delivered its highest procedure volume to date—approximately 12,200—and sold 65 new systems.
- Handpiece average selling price increased by 5% sequentially to $3,340.
- 2026 revenue guidance reset to $390M–$410M, down from previous expectations, citing short-term disruption from sales force realignment.
The big picture
PROCEPT BioRobotics is navigating a strategic pivot to focus on durable procedure growth, which led to a short-term revenue shortfall. The company's realignment of its commercial organization and pricing strategy reflects broader industry trends toward operational efficiency and disciplined financial management in the competitive surgical robotics market. The reset in 2026 revenue guidance underscores the challenges of balancing growth with profitability.
What we're watching
- Execution Risk
- Whether PROCEPT BioRobotics can sustain procedure growth while integrating its commercial realignment.
- Market Positioning
- The pace at which the company can align handpiece sales with procedure volumes to improve financial performance.
- Financial Discipline
- How the company's disciplined handpiece pricing strategy will impact margins and long-term profitability.
Our editorial coverage:
Related topics